- Home
- TII vs HELP Comparison
TII vs HELP Comparison
Compare TII & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TII | HELP |
|---|---|---|
| Founded | 2012 | N/A |
| Country | Canada | Canada |
| Employees | 167 | 50 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 219.2M | 233.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TII | HELP |
|---|---|---|
| Price | $2.42 | $5.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $6.38 | ★ $51.50 |
| AVG Volume (30 Days) | 1.3M | ★ 1.3M |
| Earning Date | 05-11-2026 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.20 | N/A |
| Revenue Next Year | $3.46 | N/A |
| P/E Ratio | $25.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.81 | $3.76 |
| 52 Week High | $5.65 | $8.55 |
Technical Indicators
Market Signals| Indicator | TII | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 56.51 | 59.46 |
| Support Level | $1.99 | $5.76 |
| Resistance Level | $2.44 | $6.26 |
| Average True Range (ATR) | 0.28 | 0.44 |
| MACD | 0.03 | 0.16 |
| Stochastic Oscillator | 55.55 | 60.71 |
Price Performance
Historical ComparisonAbout TII Titan Mining Corporation
Titan Mining Corp is a Canadian natural resources company. The company is engaged in the acquisition, exploration, development, and extraction of mineral properties. The company owns an interest in the Empire State Mine in Northern New York State, United States, and Kilbourne Graphite Project. The Company operates one reportable segment, mineral production and exploration in the United States.
About HELP Cybin Inc. Common Stock
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.